Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure

被引：6

作者：

Gilbert E.M. ^{[1
]}

Port J.D. ^{[2
]}

机构：

[1] Division of Cardiology, Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT

[2] Division of Cardiology and Department of Pharmacology, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262

来源：

Current Cardiology Reports | 2000年 / 2卷 / 3期

关键词：

Heart Failure; Chronic Heart Failure; Metoprolol; Carvedilol; Adrenergic Receptor;

D O I：

10.1007/s11886-000-0073-7

中图分类号：

学科分类号：

摘要：

In this article, we review the basic biology, signal transduction pathways, and clinical pharmacology associated with cardiac b-adrenergic receptors (b-ARs) in the context of the use of b-blocking agents in patients with chronic congestive heart failure. Adrenergic receptors, particularly the b-AR subtypes (b1-AR and b2-AR), are known to play a critical role in the modulation of cardiac function, providing for both "adaptive" and "maladaptive" compensatory changes. In the context of exercise or self-preservation, the adrenergic nervous system, acting via b-ARs permits an appropriately rapid, highly-dynamic increase in cardiac function. Conversely, in individuals with chronic congestive heart failure, the sustained, heightened activation of adrenergic nervous system, as manifested by increases in circulating catecholamines, results in downregulation and desensitization of myocardial b-ARs, and potentially, significant myocardial damage. A number of recent clinical trials have demonstrated a marked mortality benefit from using b-blocking agents such as metoprolol and carvedilol in patients with heart failure. The pharmacologic properties of several of these drugs and some of the specifics of their usefulness and limitations are discussed herein. Copyright © 2000 by Current Science Inc.

引用

页码：225 / 232

页数：7

共 57 条

[41]

Xamoterol in severe heart failure, Lancet, 336, 8716, (1990)

[42]

Eichhorn E.J., Heesch C.M., Barnett J.H., Et al., Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study, J Am Coll Cardiol, 24, pp. 1310-1320, (1994)

[43]

Lowes B.D., Gill E.A., Abraham W.T., Et al., Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure, Am J Cardiol, 83, pp. 1201-1205, (1999)

[44]

Olsen S.L., Gilbert E.M., Renlund D.G., Et al., Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study [see comments], J Am Coll Cardiol, 25, pp. 1225-1231, (1995)

[45]

Hall S.A., Cigarroa C.G., Marcoux L., Et al., Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade, J Am Coll Cardiol, 25, pp. 1154-1161, (1995)

[46]

Bristow M.R., Gilbert E.M., Abraham W.T., Et al., Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators [see comments], Circulation, 94, pp. 2807-2816, (1996)

[47]

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial [see comments], Lancet, 353, pp. 9-13, (1999)

[48]

Packer M., Bristow M.R., Cohn J.N., Et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group [see comments], N Engl J Med, 334, pp. 1349-1355, (1996)

[49]

Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [see comments], Lancet, 353, pp. 2001-2007, (1999)

[50]

Gilbert E.M., Abraham W.T., Olsen S., Et al., Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart, Circulation, 94, pp. 2817-2825, (1996)

← 1 2 3 4 5 6 →